Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy
European Journal of Cancer2011Vol. 47(17), pp. 2560–2567
Citations Over TimeTop 10% of 2011 papers
Lieke H. J. Simkens, Miriam Koopman, Linda Mol, G.J. Veldhuis, Daan ten Bokkel Huinink, E.W. Muller, Veerle A. Derleyn, Steven Teerenstra, Cornelis J.A. Punt
Related Papers
- → Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study(2021)4 cited
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer(2012)
- → Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer(2014)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)